Hero CMP-20 CBGA vs CBDA
Home/Compare/CBGa vs CBDa

CBGa vs CBDa: The Precursor and What One Enzyme Makes of It

CBGa is the acid precursor the cannabis plant builds every other cannabinoid from. CBDa is one of the three things it gets turned into, by an enzyme called CBDA synthase, and in a CBD-type cultivar that is where almost all of the CBGa ends up.

Neither has been tested on its own in a controlled human trial. The CBG sold as a product is the CBGa those enzymes never reached, after heat strips its acid group.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
CBGa
CBDa
What it is
The first cannabinoid the plant assembles, from olivetolic acid and geranyl pyrophosphate
The acid form of CBD, dominant in fresh unheated CBD-type hemp
Where it comes from
Made by the plant, then consumed by three competing synthase enzymes
Made from CBGa by CBDA synthase, a 74 kDa enzyme needing no cofactor
CB1 receptor
No published binding affinity at CB1
Ki above 10,000 nM at human CB1 in CHO cell membranes
CB2 receptor
No published binding affinity at CB2
Ki 12 nM at human CB2, reaching only 32% of reference effect on cAMP
Most potent measured target
Store-operated calcium entry, where it beat every other cannabinoid tested in immune cell lines
5-HT1A, raising agonist-stimulated GTP binding in rat brainstem membranes
Intoxicating
No, and no human dose of it has been studied
No, including in the one human study of a product containing it
Human trials
None of isolated CBGa
None of isolated CBDa. One 15-person study used a 1:1 CBD to CBDa product
Human pharmacokinetics
None published. The absorption data is from dogs and horses
Peak plasma concentration 19 to 25 times that of CBD in the same product

The enzyme that decides which one you get

Cannabis does not make CBD, THC or CBC. It makes CBGa, and three enzymes then compete to cyclize it into CBDa, THCa or CBCa. Which of those enzymes a plant carries in working form is what fixes its chemotype before a single flower is harvested.

CBDA synthase was purified in 1996 and described as a single 74 kDa polypeptide with an isoelectric point of 6.1. It needs no coenzyme, no molecular oxygen, no hydrogen peroxide and no metal ion, which rules it out as an oxygenase or a peroxidase. It will accept cannabinerolic acid as well as CBGa, but the turnover number is 0.19 per second for CBGa against 0.03 per second for the alternative, which is why CBDa in a real plant comes overwhelmingly from CBGa.

That settles what a CBGa figure on a certificate means. CBGa is unconsumed substrate, not a separate ingredient the plant adds. Varieties with a defective synthase accumulate it because nothing draws it down, and an early harvest leaves more behind. Heat then separates the paths again, turning residual CBGa into CBG and CBDa into CBD.

Where each acid has a real measured effect

CMP-20 CBGA vs CBDA second section

CBGa’s strongest documented activity is not at a cannabinoid receptor at all. Screened against store-operated calcium entry in several immune cell lines, the acid cannabinoids outperformed CBD and THC, and CBGa was the most potent of the set, blocking calcium release-activated calcium currents and reducing NFAT activation and interleukin 2 production in human T lymphocytes. A companion study found CBGa the strongest cannabinoid inhibitor of the TRPM7 channel, and showed the effect requires TRPM7’s kinase domain to be functional.

CBDa’s standout result sits at 5-HT1A, where it increased the maximum effect of a 5-HT1A agonist on GTP binding in rat brainstem membranes. The animal work that followed used doses far below anything used for CBD: vomiting in shrews was reduced at 0.1 and 0.5 mg per kilogram, and conditioned gaping in rats at 0.01 and 0.1 mg per kilogram. Both acids also bind the SARS-CoV-2 spike protein with micromolar affinity.

Every one of those findings is a cell line or an animal model, and that is the limit of what can be said. Both acids are pharmacologically interesting, and neither is pharmacologically established in people at any dose.

The evidence, side by side

CBGa
In Scn1a+/- mice, CBGa raised the threshold for hyperthermia-induced seizures and added to the anticonvulsant effect of clobazam, the strongest result in a screen of the whole plant.
In the same study CBGa was proconvulsant in the 6 Hz threshold test, and a high dose increased spontaneous seizure frequency in those mice.
No controlled human trial of isolated CBGa has been published, so no human dose range for it exists.
CBDa
In 15 healthy adults given a 1:1 CBD to CBDa product, CBDa peak plasma concentration was 19 to 25 times that of CBD and arrived up to twice as early.
That product also contained THC and THCa, so none of the subjective or cognitive effects it produced can be assigned to CBDa.
CBDa reduced motion-induced and toxin-induced vomiting in shrews at 0.1 and 0.5 mg per kilogram, through 5-HT1A rather than CB1.
No controlled human trial of isolated CBDa has been published, and no efficacy endpoint has been tested in people.

The asymmetry is worth holding onto. CBDa has the better animal pharmacology and the only human absorption figure of the two, and that figure came from a mixture rather than from CBDa alone. CBGa has the more striking in vitro potency.

What people get wrong

01The acids are the same compounds with a spare piece attached.
The carboxyl group changes receptor behavior. CBDa does not displace a cannabinoid ligand from CB1 at 10,000 nM where CBD manages it weakly, and the acids reach higher peak plasma concentrations faster than their neutral forms.
02Raw oil is stronger because nothing has been destroyed.
Heating converts the acids rather than destroying activity, so raw and decarboxylated extracts differ in profile, not in strength. For the acid forms there is no human efficacy data to be stronger or weaker than.
03CBGa is rare, so it must be valuable.
CBGa is leftover substrate. Varieties with a defective synthase accumulate it, and an early harvest leaves more of it behind. Scarcity in ordinary hemp is an agronomic fact rather than a pharmacological one.

Choosing between them

In practice this is not a choice between two products. It is a choice about heat. An unheated full spectrum extract carries CBDa as its main cannabinoid with CBGa present in smaller amounts, because both survive when the material is never decarboxylated. A decarboxylated extract from the same biomass gives you CBD and CBG instead.

So you are choosing a profile rather than an evidence base. For the most measured activity in living animals, that is CBDa. For the most potent single in vitro measurement, that is CBGa. For human outcome data, neither qualifies.

Still weighing up the options? See CBGA vs CBG, CBDa vs CBD or CBDA vs THCA. Endoca products related to this comparison: Raw CBD + CBDa oil and CBD/CBDa oil 15%.

How Endoca tests for this

Our HPLC panel quantifies acid and neutral forms as separate analytes, which is the only way to prove an unheated extract is actually unheated. A raw batch should show CBDa dominant with CBG and CBD low, and a decarboxylated batch the reverse. Where a cannabinoid falls below the limit of quantification we report it that way instead of estimating it. What a certificate cannot tell you is what either acid does at a receptor.

Frequently asked questions

Yes. CBDA synthase converts CBGa directly into CBDa, with a turnover number of 0.19 per second. The same precursor also feeds THCa and CBCa synthase, so the three acids compete for one pool of CBGa, and which enzymes a plant carries decides its chemotype.

Both, in very different amounts. An unheated CBD-type extract is dominated by CBDa, because the plant’s enzymes converted most of the available CBGa before harvest. CBGa appears in smaller amounts as unconsumed substrate. Heating the same material converts CBDa to CBD and residual CBGa to CBG.

CBDa does, and efficiently. In 15 healthy adults taking a product with equal parts CBD and CBDa, the acid reached peak plasma concentrations 19 to 25 times higher, and reached them sooner. No equivalent human measurement has been published for CBGa, only data in dogs and horses.

Not on the evidence available. Neither acid has a controlled human trial, so there is no outcome to set against CBD, which has three regulatory-grade epilepsy trials behind it. The acids absorb better and behave differently at receptors. Better absorption is not the same as better results.

There is no trial comparing them together with either alone. Raw hemp extracts naturally contain both, alongside other acids.

As the plant matures, enzymes convert most of its CBGA into other acids, mainly CBDA in hemp. Only a small residual amount of CBGA is usually left at harvest.

References

01

Taura F, Morimoto S, Shoyama Y. Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. J Biol Chem 1996;271:17411-17416.

02

Taura F et al. Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa. FEBS Lett 2007;581:2929-2934.

03

Anderson LL et al. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. Br J Pharmacol 2021;178:4826-4841.

04

Faouzi M et al. Acidic cannabinoids suppress proinflammatory cytokine release by blocking store-operated calcium entry. Function (Oxf) 2022;3:zqac033.

05

Suzuki S et al. Cannabigerolic acid (CBGA) inhibits the TRPM7 ion channel through its kinase domain. Function (Oxf) 2024;5:zqad069.

06

Bolognini D et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 2013;168:1456-1470.

07

Zagzoog A et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10:20405.

08

Elder HJ et al. The pharmacokinetics and pharmacodynamics of a hemp-derived full-spectrum oral cannabinoid product with a 1:1 ratio of cannabidiol to cannabidiolic acid. Cannabis Cannabinoid Res 2025;10:e299-e313.

09

De Petrocellis L et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479-1494.

10

van Breemen RB et al. Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. J Nat Prod 2022;85:176-184.

11

Congressional Research Service. Changes to the statutory definition of hemp and issues for Congress. In Focus IF13136, 17 August 2026.

Last reviewed 6 October 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.